Trial Profile

A Cancer Research UK Phase I Study of MOv18 IgE, a First in Class Chimeric IgE Antibody Against Folate Receptor-alpha, in Patients With Advanced Solid Tumours

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MOv18 IgE (Primary)
Indications Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man

Most Recent Events

25 Jul 2023 Results presented in the Epsilogen Media Release.
25 Jul 2023 According to an Epsilogen company media release, final data from the study were published in the Nature Communications.
11 Jun 2023 According to an Epsilogen company website, data from this study were presented at the European Academy of Allergy & Clinical Immunology (EAACI).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com